Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-11
DOI
10.3389/fonc.2021.680758
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-Inflammatory Action and Mechanisms of Resveratrol
- (2021) Tiantian Meng et al. MOLECULES
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- (2020) Kerstin N. Timm et al. CARDIOVASCULAR DRUGS AND THERAPY
- Real-World Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score
- (2020) Manuela Schmidinger et al. Clinical Genitourinary Cancer
- Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis
- (2020) Anita A. Pinar et al. PHARMACOLOGY & THERAPEUTICS
- Resveratrol in Cancer Patients: From Bench to Bedside
- (2020) Massimiliano Berretta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
- (2020) Justus Huelse et al. PHARMACOLOGY & THERAPEUTICS
- Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
- (2020) Charles Pottier et al. Cancers
- Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study
- (2020) Massimiliano Berretta et al. Frontiers in Oncology
- The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation
- (2020) Alexander Hooftman et al. Cell Metabolism
- NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword
- (2020) Shaima'a Hamarsheh et al. Frontiers in Immunology
- NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
- (2020) Vincenzo Quagliariello et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer
- (2020) Margherita Sonnessa et al. Frontiers in Oncology
- Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
- (2020) Vincenzo Quagliariello et al. Journal of Personalized Medicine
- Inhibiting the NLRP3 Inflammasome
- (2020) Lina Y. El-Sharkawy et al. MOLECULES
- Anti-cancer strategy targeting the energy metabolism of tumor cells surviving a low-nutrient acidic microenvironment
- (2020) Yuki Maeda et al. Molecular Metabolism
- Effect of the Nrf2‑ARE signaling pathway on biological characteristics and sensitivity to sunitinib in renal cell carcinoma
- (2019) Shiliang Ji et al. Oncology Letters
- Polydatin alleviates traumatic spinal cord injury by reducing microglial inflammation via regulation of iNOS and NLRP3 inflammasome pathway
- (2019) Runxiao Lv et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis
- (2019) Benjamin Castagné et al. PLoS One
- An NLRP3 inflammasome-triggered cytokine storm contributes to Streptococcal toxic shock-like syndrome (STSLS)
- (2019) Lan Lin et al. PLoS Pathogens
- Polydatin Attenuates Neuronal Loss via Reducing Neuroinflammation and Oxidative Stress in Rat MCAO Models
- (2019) Fawad Ali Shah et al. Frontiers in Pharmacology
- Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825
- (2019) Xin Wang et al. ONCOLOGY REPORTS
- Protective Effect of RIVA Against Sunitinib-Induced Cardiotoxicity by Inhibiting Oxidative Stress-Mediated Inflammation: Probable Role of TGF-β and Smad Signaling
- (2019) Faisal Imam et al. Cardiovascular Toxicology
- Polydatin Inhibits NLRP3 Inflammasome in Dry Eye Disease by Attenuating Oxidative Stress and Inhibiting the NF-κB Pathway
- (2019) Bongkyun Park et al. Nutrients
- Polydatin and Resveratrol Inhibit the Inflammatory Process Induced by Urate and Pyrophosphate Crystals in THP-1 Cells
- (2019) Francesca Oliviero et al. Foods
- Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer
- (2019) Carmine D'Aniello et al. Frontiers in Oncology
- Polydatin Improves Glucose and Lipid Metabolisms in Insulin-Resistant HepG2 Cells through the AMPK Pathway
- (2018) Jie Hao et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Tumor–Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer
- (2018) Daoxiang Zhang et al. CANCER RESEARCH
- Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
- (2018) Hirotake Tsukamoto et al. CANCER RESEARCH
- Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib
- (2018) Gracia M. Amaya et al. CHEMICAL RESEARCH IN TOXICOLOGY
- NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
- (2018) Alena Grebe et al. CIRCULATION RESEARCH
- The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases
- (2018) Mariuxi A. Viteri Malone et al. Clinical Genitourinary Cancer
- Polydatin Protects Diabetic Heart against Ischemia-Reperfusion Injury via Notch1/Hes1-Mediated Activation of Pten/Akt Signaling
- (2018) Liming Yu et al. Oxidative Medicine and Cellular Longevity
- Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib
- (2018) Stefania Gorini et al. Oxidative Medicine and Cellular Longevity
- Polydatin inhibits the IL-1β-induced inflammatory response in human osteoarthritic chondrocytes by activating the Nrf2 signaling pathway and ameliorates murine osteoarthritis
- (2018) Shangkun Tang et al. Food & Function
- NLRP3: A Novel Mediator in Cardiovascular Disease
- (2018) Wenyi Zhou et al. Journal of Immunology Research
- Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-κB pathway
- (2018) Jun Zou et al. BIOMEDICINE & PHARMACOTHERAPY
- Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target
- (2018) Juho Heliste et al. BMC Cardiovascular Disorders
- Role of the NLRP3 inflammasome in cancer
- (2018) Maryam Moossavi et al. Molecular Cancer
- Renal cell carcinoma presenting with heart metastasis without inferior vena caval and right atrial involvement
- (2017) Suleyman Sahin et al. Journal of Cancer Research and Therapeutics
- Polydatin impairs mitochondria fitness and ameliorates podocyte injury by suppressing Drp1 expression
- (2017) Zheng Ni et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
- (2017) Moshe C. Ornstein et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma
- (2017) Xiaodong Feng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases
- (2017) Francesca Colazzo et al. MEDIATORS OF INFLAMMATION
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy
- (2017) Hanna-Riikka Teppo et al. Oxidative Medicine and Cellular Longevity
- Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
- (2016) Mamoru Morimoto et al. BMC CANCER
- Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
- (2016) Yu Wang et al. Cardiovascular Diabetology
- Progress on the cardiotoxicity of sunitinib: Prognostic significance, mechanism and protective therapies
- (2016) Yi Yang et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors
- (2016) Nicola Maurea et al. Journal of Cardiovascular Medicine
- Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by Janus kinase 2 inhibition in leukemia cells
- (2016) WEI-JIE CAO et al. Molecular Medicine Reports
- Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey
- (2016) Massimiliano Berretta et al. Oncotarget
- Precision oncology: identifying predictive biomarkers for the treatment of metastatic renal cell carcinoma
- (2016) Parth K. Modi et al. Translational Cancer Research
- The varying faces of IL-6: From cardiac protection to cardiac failure
- (2015) Jillian A. Fontes et al. CYTOKINE
- Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse
- (2015) Carlo Marchetti et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson’s disease
- (2015) Yupin Chen et al. Molecular Neurodegeneration
- Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress
- (2015) Paweorn Angsutararux et al. Oxidative Medicine and Cellular Longevity
- Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
- (2015) Maria Serova et al. Oncotarget
- PDGF/PDGFR Signaling and Targeting in Cancer Growth and Progression: Focus on Tumor Microenvironment and Cancer-associated Fibroblasts
- (2014) Chrisostomi Gialeli et al. CURRENT PHARMACEUTICAL DESIGN
- Renal cell carcinoma with intramyocardial metastases
- (2014) Anna M Czarnecka et al. BMC Urology
- Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway
- (2013) Zaid H. Maayah et al. ARCHIVES OF TOXICOLOGY
- Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA
- (2013) Ståle H. Nymo et al. EUROPEAN JOURNAL OF HEART FAILURE
- Sunitinib enhances neuronal survival in vitro via NF-κB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase
- (2013) Alma Sanchez et al. Journal of Neuroinflammation
- Polydatin: A review of pharmacology and pharmacokinetics
- (2013) Qiao-Hui Du et al. PHARMACEUTICAL BIOLOGY
- The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β
- (2012) Nathan A. Bracey et al. EXPERIMENTAL PHYSIOLOGY
- Polydatin, A Natural Precursor of Resveratrol, Induces β-Defensin Production and Reduces Inflammatory Response
- (2012) Giampietro Ravagnan et al. INFLAMMATION
- Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
- (2012) Ezzeldin M. Ibrahim et al. International Journal of Clinical Oncology
- The Multi-Targeted Kinase Inhibitor Sunitinib Induces Apoptosis in Colon Cancer Cells via PUMA
- (2012) Jing Sun et al. PLoS One
- Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group
- (2011) G. Lainakis et al. CLINICAL NEPHROLOGY
- Anti-inflammatory Effect of Resveratrol and Polydatin by In Vitro IL-17 Modulation
- (2011) Giulia Lanzilli et al. INFLAMMATION
- New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects
- (2011) G. Aparicio-Gallego et al. MOLECULAR CANCER THERAPEUTICS
- Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
- (2011) Thomas Force et al. NATURE REVIEWS DRUG DISCOVERY
- Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations
- (2011) J.D. Cohen et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- CXCL12: A New Player in Coronary Disease Identified through Human Genetics
- (2011) Samira S. Farouk et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient
- (2010) Joan Manel Gasent Blesa et al. ANTI-CANCER DRUGS
- MyD88-dependent pro-inflammatory cytokine response contributes to lethal toxicity of staphylococcal enterotoxin B in mice
- (2010) Teri L Kissner et al. Innate Immunity
- Mono- or Double-Site Phosphorylation Distinctly Regulates the Proapoptotic Function of Bax
- (2010) Qinhong Wang et al. PLoS One
- Autophagy plays an important role in Sunitinib-mediated cell death in H9c2 cardiac muscle cells
- (2010) Yuqin Zhao et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
- (2009) G. Di Lorenzo et al. ANNALS OF ONCOLOGY
- Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
- (2009) C. L. Bello et al. CLINICAL CANCER RESEARCH
- Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase
- (2009) Risto Kerkela et al. CTS-Clinical and Translational Science
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search